Both companies may succeed in this industry.

The company got some bad news to start 2026.

Eli Lilly (LLY) has drawn fresh attention after recent price moves, with the share closing at $1,038.40. Short term returns ...

Maybe just to add to that, OUS as well, we continue to advance or engage new countries that we are going to be launching ...

A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Third-Quarter Reported Results In Q3 ...

The MarketWatch News Department was not involved in the creation of this content. -- Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. -- Increased ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech Abivax and had no contact with U.S. pharmaceutical giant Eli Lilly, ...

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day ...

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range ...